Tirzepatide decreases eGFR decline in humans (ETD 3.9 ml/min per 1.73m2, p<0.001).
“A significantly smaller decline in eGFR was observed with pooled TZP (-1.6±0.5 ml/min per 1.73m2) compared to placebo (-5.5±1.0 ml/min per 1.73m2) after 176 weeks”
Human trialin participants with obesity or overweight and prediabetes176 weeks
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·27 Aug 2021
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·27 Aug 2021
The two-year combined outcome rate was 15.6% for sodium-glucose cotransporter 2 inhibitors versus 19.9% for renin-angiotensin system inhibitors, the comparison drug…The two-year combined outcome rate was 15.6% for sodium-glucose cotransporter 2 inhibitors versus 19.9% for renin-angiotensin system inhibitors, the comparison drug class.
In geriatric wards, a heart, lung and kidney disease pattern was associated with 2.24 times the odds of decline versus two other disease patterns.In geriatric wards, a heart, lung and kidney disease pattern was associated with 2.24 times the odds of decline versus two other disease patterns.
Links to heart attacks were stronger at lower kidney function for 154 blood proteins and at higher function for 22.Links to heart attacks were stronger at lower kidney function for 154 blood proteins and at higher function for 22.
Higher fractional uric acid excretion was associated with eGFR decline after adjustment for confounders (odds ratio 1.218, 95% CI 1.176–1.262).Higher fractional uric acid excretion was associated with eGFR decline after adjustment for confounders (odds ratio 1.218, 95% CI 1.176–1.262).